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Introduction
Next generation sequencing (NGS) has transformed genetic 
medicine by dramatically reducing the cost and time of genetic 
testing, which has led to a rapid global expansion in clinical 
genetic testing1. It is obviously crucial that these tests are 
accurate, with low false positive and false negative error rates. 
Robust quality assurance and quality control are required to 
minimise these errors and thus ensure reliable test results2.
Three primary metrics are used to evaluate sequence quality in 
NGS data: depth of coverage (how many sequence reads are 
present at a given position), base quality (have the correct 
bases been called in sequence reads) and mapping quality (have 
the reads been mapped to the correct position in the genome)3. 
False negative errors are often caused by insufficient depth 
of coverage4, and it is vital that regions with low coverage 
are flagged and reviewed, not least because they may require 
additional interrogation5. Coverage evaluation is also useful for 
comparing different NGS library generation strategies, to identify 
regions with suboptimal performance6,7 and for probe design 
optimisation8.
Poor base and poor mapping quality can cause false negative 
and false positive errors. Systematic base calling errors often 
occur in regions with high or low GC content or in homopolymer 
stretches9, while mapping errors often occur in regions of high 
homology (e.g. pseudogenes) that result in ambiguously mapped 
reads10. As a starting point for evaluating base and mapping 
quality, base callers and read mappers provide Phred quality 
scores that quantify base and mapping quality. These scores 
give the probability that a particular base has been identified 
incorrectly (base quality score, BQ11) or a read has aligned to 
the wrong genomic position (mapping quality score, MQ)12.
Several tools and packages for analysing depth of coverage, 
base and mapping quality exist, for example GATK DepthOf 
Coverage and DiagnoseTargets13, QualiMap14, FastQC15, samtools 
depth16 and pysamstats17. These tools have different strengths, 
weaknesses and trade-offs, particularly in relation to flexibility 
and usability. Most available tools were developed for the 
research environment rather than the medical setting and have 
not focused on the needs and requirements of genetic testing in 
patients.
Here we present CoverView, a quality evaluation tool for NGS 
data that was designed to be user-friendly, fast, flexible and 
easy to integrate into NGS analysis pipelines. CoverView was 
developed to provide the quality assurance and quality control 
information required by clinical NGS testing laboratories, though 
we believe it is equally useful for research use. We recently 
proposed the Quality Sequencing Minimum (QSM) to deliver 
comprehensive, consistent, transparent NGS quality assurance 
information about depth of coverage, base and mapping quality, 
and we use CoverView to evaluate fulfilment of a QSM in our 
laboratory8. We also use CoverView as the quality control tool 
for all our research and clinical NGS analyses and it is integrated 
into our exome analysis tool, OpEx (Optimised Exome)18.
Methods
Implementation
CoverView is implemented as an easy-to-use tool that can 
process the read count, BQ and MQ of mapped sequencing 
reads. It reports a series of informative quality control (QC) 
metrics with increasing levels of detail from a chromosome-level 
summary to per-base profiles. It also flags regions that do not 
pass user-defined quality requirements. The tool is implemented 
in Python v.2.7.13 and Cython v.0.25.2, with its graphical user 
interface (GUI) developed in Flask v. 0.12.1, HTML5 v.5.1 and 
JQuery v.3.1.1.
CoverView requires a BAM file (containing the mapped reads) 
as its input with the corresponding .BAI file16. A BED file is 
also required with each record in the BED file defining the 
user-specified genomic region of interest (e.g. an exon of a gene) 
for which depth of coverage and sequence quality metrics will 
be reported. The BAM file may optionally contain reads marked 
as duplicates as CoverView can generate metrics with duplicate 
reads either included or excluded.
CoverView generates four output (.txt) files that provide dif-
ferent information about the quality of the input BAM dataset 
(for CoverView input files see Data and software availability 
section)19. At the most detailed level, per-base profiles of 
position specific metrics are reported for each region (Table 1). 
This base-level resolution is important because regions may only 
partially fail quality metrics, for example one part of an exon may 
have high quality depth of coverage whilst another part is poorly 
covered.
Table 1. Position specific metrics reported as per-base profiles in the specified genomic regions.
Position specific metrics Definition
Coverage (COV) The number of mapped reads covering the position
Median Base Quality (MEDBQ) Median base quality of all read bases mapping to the position
Fraction of Low Base Quality (FLBQ) Fraction of read bases mapping to the position with a base quality 
lower than a user-specified threshold
Median Mapping Quality (MEDMQ) Median mapping quality of all reads covering the position
Fraction of Low Mapping Quality (FLMQ) Fraction of reads covering the position with a mapping quality 
lower than a user-specified threshold
Quality Coverage (QCOV) Number of mapped reads covering the position with read mapping 
quality and base quality higher than user-specified threshold
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The coverage profile (COV) provides information on how the 
depth of coverage changes across the region, whilst the FLBQ 
and FLMQ metrics describe the fraction of coverage of low 
base or mapping quality scores at each position, respectively 
(Table 1). This is important because at positions with high 
FLBQ or FLMQ values it may not be possible to call variants 
with confidence even if the COV threshold is met. In addition, 
mapping and base quality scores are summarised by their 
median in the per-base MEDBQ and MEDMQ profiles. Finally, 
the QCOV profile integrates coverage, base and mapping quality 
information for each base by counting the number of covering 
reads that satisfy the user-defined quality requirements.
As systematic base calling errors can be strand-specific20, 
QC metrics for forward and reverse reads separately can be 
of interest. CoverView can, optionally, output the described 
profiles calculated for forward (+) and reverse (-) reads only, 
facilitating detection of strand-specific biases in coverage or base 
and mapping quality.
Summary statistics derived from the per-base profiles are reported 
for each user-specified region to describe the overall quality 
of the region (Table 2)19. MEDCOV and MEDQCOV summa-
rise the coverage profiles by their median across positions and 
MINCOV and MINQCOV provide information about the least 
covered position. Finally, the MAXFLMQ and MAXFBLQ 
metrics describe the lowest sequence quality positions in the 
region. CoverView can also output region-level metrics calculated 
for forward and reverse reads separately.
Users can define the minimal requirements to ‘pass’ the quality 
test and if this is not met the region of interest is ‘flagged’. Defin-
ing these minimum requirements for depth of coverage, base 
and mapping quality are the basis of the QSM that is described 
in detail in the accompanying paper8. In CoverView a mini-
mum or maximum value can be specified for any of the metrics 
in Table 2. For example, users may set a lower threshold to 
MINCOV and an upper threshold to MAXFLBQ: i.e. a region will 
be tagged with “FLAG” if coverage is below the defined value 
or FLBQ exceeds the maximum value at any position within the 
region, otherwise the region will be tagged as “PASS”. A separate 
column in the output file indicates the pass/flag status of each 
region.
For correct variant annotation, interpretation and follow-up it 
is essential to know which gene transcripts a flagged region 
overlap with. A simple script (ensembl_db) is included for 
creating a transcript database using any Ensembl release. In a 
separate output file, CoverView optionally reports the transcript 
coordinates (CSN coordinates21) of all genomic intervals that are 
covered by less than 15 high quality reads (QCOV<15), which 
are referred to as “poor quality intervals”19. Users may wish to 
review positive or negative calls within such regions, to ensure 
confidence in the calls.
CoverView also provides a chromosome-level summary19. This 
is important because the input BAM file may contain unmapped 
reads or reads that are mapped outside the targeted regions. 
In order to quantify the fraction of sequencing data that are not 
useful for variant calling within regions in the BED file, Cover-
View creates a chromosome-level summary that reports the total 
read counts (RC) and the read counts of on-target (RCIN) and 
off-target regions (RCOUT) for each chromosome. In addition, 
the outputted table includes the mapped, unmapped and total 
read counts calculated for the whole genome.
Finally, CoverView provides a GUI with multiple views (‘Anal-
ysis View’, ‘Genes View’, ‘Regions View’, ‘Profiles View’), 
that allow users to intuitively explore the results. The Analysis 
View shows metadata of the analysis such as the names of input 
files and key configuration options. The Genes View offers a 
clickable bar plot displaying per-chromosome read counts (both 
on-target and off-target) and a filterable table providing infor-
mation on the number of flagged regions for each gene on the 
selected chromosome (Figure 1). The Regions View displays 
a scrollable, searchable and filterable table of region-specific 
metrics values (Table 2) with flagged regions and the metric(s) 
underlying the flag highlighted (Figure 2). The Profiles View 
provides an interactive table and graph of per-base quality 
profiles for a selected region aligned with the corresponding 
reference genome sequence. Users can change the metrics 
displayed, zoom in, or navigate along the sequence with 
Table 2. Summary metrics for the specified genomic regions.
Summary metrics of region Definition
Read count (RC) Total number of mapped reads overlapping the region
Median coverage (MEDCOV) Median of COV values across all positions in the region
Minimum coverage (MINCOV) Minimum of COV values across all positions in the region
Median quality coverage (MEDQCOV) Median of QCOV values across all positions in the region
Minimum quality coverage (MINQCOV) Minimum of QCOV values across all positions in the region
Maximum fraction of low mapping quality (MAXFLMQ) Maximum of FLMQ values across all positions in the region
Maximum fraction of low base quality (MAXFLBQ) Maximum of FLBQ values across all positions in the region
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Figure 1. CoverView GUI Genes View for TSCP analysis in GIAB sample. CoverView GUI screenshot of the Genes View for TruSight 
Cancer Panel (TSCP) data generated for the Genome in a Bottle (GIAB) sample shows a bar plot of per-chromosome read counts and the list 
of flagged regions. Nine regions in eight genes were flagged for falling below MINQCOV ≥50 in the GIAB sample.
Figure 2. CoverView GUI Regions View for PMS2 in GIAB sample. CoverView GUI screenshot of Regions View for PMS2 data in the 
GIAB sample showing the summary metrics per region. Metrics that fall below user-defined thresholds are shown in red and flagged. The 
MINQCOV for PMS2 exons 12 and 15 are below MINQCOV ≥50.
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quality minimum thresholds overlaid as dashed horizontal lines 
(Figure 3, Figure 4). The GUI is a Flask application that runs in 
the web browser on port 5000.
Operation
CoverView can be installed by running a simple Bash script. 
Installation requires Python v.2.7.9 or later (Python2 series), 
GCC v.4.2.1, GNU make v.3.81 and virtualenv v.15.1.022. 
Note that Python v.2.7.9 and later include pip by default. 
Additional dependencies (e.g. the Python module pysam23) are 
automatically downloaded and set up in an isolated Python 
virtual environment by the installation script.
Once installed, the tool can be customised with a simple INI 
configuration file and run from Linux/Unix command line (see 
Documentation for details). CoverView can be easily integrated 
into NGS analysis pipelines, as shown for the OpEx (Optimised 
Exome)18 pipeline. The CoverView documentation is hosted 
on GitHub Pages at https://rahmanteamdevelopment.github.io/ 
CoverView/
CoverView v.1.4.3 documentation is also included in 
Supplementary File 1.
Use case
We use the TruSight Cancer Panel (TSCP) for testing cancer 
predisposition genes in both research and clinical settings24–26. 
Here we generated TSCP data on the National Institute of 
Standards and Technology (NIST) Reference Material (RM) 
8398, for which there are experimentally validated genotyped 
sites provided by the NIST-led Genome in a Bottle (GIAB) 
Consortium27. We mapped paired-end Illumina sequencing 
reads to the human reference genome (GRCh37) using Stampy 
v.1.0.2028 with BWA v.0.7.5a29 for pre-mapping. Duplicate reads 
were marked with Picard v.1.9030. The resulting BAM file was 
analysed with CoverView v.1.4.3 with a BED file specifying the 
TSCP targeted regions. Duplicate reads were included in the 
analysis. In this use case we set the minimal requirement for a 
region to ‘PASS’ as MINQCOV ≥50: i.e. all base positions in a 
targeted region were required to be covered by at least 50 reads 
of good quality (MQ ≥ 20 and BQ ≥10). The CoverView analysis 
was completed in 13 seconds (for CoverView Output files 
see Data and software availability section)19.
Nine of the 1471 targeted regions, affecting eight genes, were 
flagged as not fulfilling the MINQCOV ≥50 requirement 
(Figure 1)19. Here we focus on PMS2 exon 12 as an example of 
Figure 3. CoverView GUI Profiles View showing PMS2 exon 12 COV and QCOV data in GIAB sample. CoverView GUI screenshot of 
Profiles View for PMS2 exon 12 data in the GIAB sample showing the quality coverage QCOV (blue), per-base coverage COV (red) and the 
minimum QCOV threshold as dashed horizontal lines, across the region. The useful (quality) coverage is only a small proportion of the total 
coverage.
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Figure 4. CoverView GUI Profiles View showing PMS2 exon 12 QCOV and FLMQ data in GIAB sample. CoverView GUI screenshot of 
Profiles View for PMS2 exon 12 data in the GIAB sample showing the quality coverage QCOV (blue), fraction of read bases with low mapping 
quality FMLQ (red) and the minimum QCOV threshold as dashed horizontal lines, across the region. This shows that the majority of reads 
mapping to this region have low mapping quality.
how the CoverView GUI can help to investigate the underlying 
reasons of poor quality.
The Regions View provides region-level metrics values for PMS2 
exon 12 (Figure 2). The table shows that 3404 reads were mapped 
to this region. Although the least covered base has 173 reads 
(MINCOV=173), one part of the region was covered with only 
30 reads of good quality (MINQCOV=30). The MINQCOV col-
umn is therefore highlighted in red, indicating that its value is 
below the pre-set quality requirement. The table also suggests 
that the large difference between MINCOV and MINQCOV is 
due to poor mapping quality because the fraction of low mapping 
quality reads in the region is very high (MAXFLMQ=0.9; at a 
given position 90% of reads did not fulfill MQ ≥ 20). This is 
further supported by the Profiles View which shows the COV 
and QCOV metrics together (Figure 3). These two depth of 
coverage profiles along the entire exon are substantially different, 
and the FLMQ profile shows that the mapping quality is consist-
ently poor (FLMQ>0.8) along the whole exon (Figure 4). This 
explains the striking difference between the COV and QCOV 
profiles since low quality reads are not counted as part of quality 
depth of coverage. PMS2 has a nearby pseudogene with strong 
homology to exons 9, 11–15 that causes ambiguous mapping 
and it is not possible to robustly analyse exon 12 by TSCP 
data alone8. However, the CoverView outputs show that every 
base in 1462/1471 (99%) TSCP regions in the GIAB sample pass 
the MINQCOV ≥50 quality threshold19.
Conclusion
Next generation sequencing data are error-prone, subject to 
random errors affecting individual samples and systematic 
errors, due to sequence contexts and biases of sequencing 
platforms, affecting many samples. Stringent, comprehen-
sive quality management is therefore essential when using 
NGS for clinical applications. CoverView is a freely avail-
able NGS quality evaluation tool that provides quality metrics at 
the highest possible resolution by outputting per-base profiles, 
together with informative summary metrics that highlight which 
areas require further review. The CoverView outputs can be 
integrated into NGS pipelines so that regions that pass user- 
defined thresholds can automatically proceed and regions flagged 
as falling below user-defined thresholds can be further evaluated. 
The CoverView GUI provides a simple, visual interface with 
which to explore CoverView outputs and to investigate flagged 
regions. 
We developed CoverView to be easy to install and use and we 
believe it can be quickly integrated into any NGS pipelines. 
CoverView is now the quality evaluation tool we use for all our 
clinical and research NGS analyses.
Data and software availability
CoverView input and output files for TSCP analysis in GIAB 
sample are available at: http://doi.org/10.17605/OSF.IO/87K6S19
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Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
CoverView is available at: github.com/RahmanTeamDevelopment/
CoverView/releases and www.icr.ac.uk/CoverView
CoverView documentation is available at: https:// 
rahmanteamdevelopment.github.io/CoverView/
Latest source code: https://github.com/RahmanTeamDevelopment/
CoverView




Supplementary File 1. CoverView v.1.4.3 documentation.
Click here to access the data.
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